Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5733-5743

  Oren, Ravit ^a   Hod Marco, Moran ^a   Haus Cohen, Maya ^a   Thomas, Sharyn ^b   Blat, Dan ^c   Duvshani, Nerri ^a   Denkberg, Galit ^d   Elbaz, Yael ^d   Benchetrit, Fabrice ^d   Eshhar, Zelig ^c   Stauss, Hans ^b   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Applied Immune Technologies Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HLA A2 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; WT1 PROTEIN; ANTIBODY; CANCER VACCINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ANTIBODY AFFINITY; ARTICLE; CELL ENGINEERING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; COMPARATIVE STUDY; CYTOTOXICITY; GENETIC ENGINEERING; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANTIBODIES; ANTIBODY AFFINITY; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; GENETIC ENGINEERING; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84912569473     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301769     Document Type: Article

References (50)

1. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
2. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
3. Besser, M. J., R. Shapira-Frommer, A. J. Treves, D. Zippel, O. Itzhaki, L. Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, et al. 2010. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16: 2646-2655.
4. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
5. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
6. Cohen, C. J., Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan. 2005. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175: 5799-5808.
7. Xue, S. A., L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, and H. Stauss. 2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106: 3062-3067.
8. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
9. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
10. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
11. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29: 917-924.
12. Uttenthal, B. J., I. Chua, E. C. Morris, and H. J. Stauss. 2012. Challenges in T cell receptor gene therapy. J. Gene Med. 14: 386-399.
13. Gross, G., T. Waks, and Z. Eshhar. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86: 10024-10028.
14. Eshhar, Z. 2008. The T-body approach: redirecting T cells with antibody specificity. Exp. Pharmacol. 329-342.
15. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. 2006. A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115.
16. Pule, M. A., B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. Huls, E. Liu, A. P. Gee, Z. Mei, et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14: 1264-1270.
17. Kochenderfer, J. N., W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
18. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
19. Jena, B., G. Dotti, and L. J. Cooper. 2010. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044.
20. Cheever, M. A., J. P. Allison, A. S. Ferris, O. J. Finn, B. M. Hastings, T. T. Hecht, I. Mellman, S. A. Prindiville, J. L. Viner, L. M.Weiner, and L. M. Matrisian. 2009. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15: 5323-5337.
21. Inoue, K., H. Ogawa, Y. Sonoda, T. Kimura, H. Sakabe, Y. Oka, S. Miyake, H. Tamaki, Y. Oji, T. Yamagami, et al. 1997. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89: 1405-1412.
22. Oji, Y., H. Ogawa, H. Tamaki, Y. Oka, A. Tsuboi, E. H. Kim, T. Soma, T. Tatekawa, M. Kawakami, M. Asada, et al. 1999. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90: 194-204.
23. Yamagami, T., H. Sugiyama, K. Inoue, H. Ogawa, T. Tatekawa, M. Hirata, T. Kudoh, T. Akiyama, A. Murakami, and T. Maekawa. 1996. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87: 2878-2884.
24. Oka, Y., O. A. Elisseeva, A. Tsuboi, H. Ogawa, H. Tamaki, H. Li, Y. Oji, E. H. Kim, T. Soma, M. Asada, et al. 2000. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51: 99-107.
25. Gao, L., I. Bellantuono, A. Elsässer, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss. 2000. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203.
26. Dahan, R., and Y. Reiter. 2012. T-cell-receptor-like antibodies - generation, function and applications. Expert Rev. Mol. Med. 14: e6.
27. Cohen, C. J., G. Denkberg, A. Lev, M. Epel, and Y. Reiter. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16: 324-332.
28. Denkberg, G., C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426.
29. Griffiths, A. D., S. C. Williams, O. Hartley, I. M. Tomlinson, P. Waterhouse, W. L. Crosby, R. E. Kontermann, P. T. Jones, N. M. Low, T. J. Allison, et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13: 3245-3260.
30. Sergeeva, A., G. Alatrash, H. He, K. Ruisaard, S. Lu, J. Wygant, B. W. McIntyre, Q. Ma, D. Li, L. St John, et al. 2011. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117: 4262-4272.
31. Davis, M. M., J. J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 1998. Ligand recognition by alpha beta T cell receptors. Annu. Rev. Immunol. 16: 523-544.
32. Stone, J. D., A. S. Chervin, and D. M. Kranz. 2009. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126: 165-176.
33. Denkberg, G., C. J. Cohen, D. Segal, A. F. Kirkin, and Y. Reiter. 2000. Recombinant human single-chain MHC-peptide complexes made from E. coli By in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30: 3522-3532.
34. Bronner, V., G. Denkberg, M. Peled, Y. Elbaz, E. Zahavi, H. Kasoto, Y. Reiter, A. Notcovich, and T. Bravman. 2010. Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system. Anal. Biochem. 406: 147-156.
35. Oved, K., O. Ziv, J. Jacob-Hirsch, R. Noy, H. Novak, O. Makler, D. Galit, S. Keren, D. Segal, C. Gefen-Dor, et al. 2007. A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy. J. Immunol. 178: 2307-2317.
36. Friedmann-Morvinski, D., A. Bendavid, T. Waks, D. Schindler, and Z. Eshhar. 2005. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105: 3087-3093.
37. Eshhar, Z., T. Waks, A. Bendavid, and D. G. Schindler. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248: 67-76.
38. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90: 720-724.
39. Thomas, S., S. A. Xue, M. Cesco-Gaspere, E. San José, D. P. Hart, V. Wong, R. Debets, B. Alarcon, E. Morris, and H. J. Stauss. 2007. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179: 5803-5810.
40. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
41. Kantoff, P.W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al IMPACT Study Investigators. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
42. Dunn, S. M., P. J. Rizkallah, E. Baston, T. Mahon, B. Cameron, R. Moysey, F. Gao, M. Sami, J. Boulter, Y. Li, and B. K. Jakobsen. 2006. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15: 710-721.
43. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
44. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180: 6116-6131.
45. Reichert, J. M., and E. Dhimolea. 2012. The future of antibodies as cancer drugs. Drug Discov. Today 17: 954-963.
46. May, C., P. Sapra, and H. P. Gerber. 2012. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem. Pharmacol. 84: 1105-1112.
47. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62.
48. Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J. C. Sarria, R. Gomez-Eerland, M. Thome, T. N. Schumacher, P. Romero, et al. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184: 4936-4946.
49. Thomas, S., S. A. Xue, C. R. Bangham, B. K. Jakobsen, E. C. Morris, and H. J. Stauss. 2011. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 118: 319-329.
50. Appay, V., D. C. Douek, and D. A. Price. 2008. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14: 623-628.